The mechanism: oxygen, angiogenesis, and graft survival

What problem is HBOT trying to solve after a hair transplant?

A transplanted follicular unit is cut off from its blood supply and survives only on plasmatic imbibition — diffusion of oxygen and nutrients from tissue fluid — for days until new vessels connect it. That ischaemic window is graft survival's recognised vulnerability, and HBOT targets exactly this window by improving available oxygen.

When a follicular unit is removed from the donor area it is cut off from its blood supply. Once it is placed in a recipient incision it has no circulation of its own for a period measured in days. During that interval it survives on plasmatic imbibition — oxygen and nutrients diffusing in from surrounding tissue fluid — until new vessels grow in and connect.

That ischaemic window is the recognised vulnerability in graft survival. The review literature on factors affecting follicular graft growth, summarised by Parsley and Perez-Meza, treats time out of the body, handling trauma, desiccation and the recipient-site environment as the levers that determine how many grafts survive. Anything that improves the oxygen available to a graft while it is still dependent on diffusion is, in principle, working on a genuine problem.

This is why the idea is not silly. It targets the right window with the right physiological variable.

Why does breathing oxygen under pressure change how much reaches tissue?

At sea level, tissue oxygen is carried almost entirely by haemoglobin, already about 97% saturated, so breathing more oxygen adds little. But oxygen dissolved in plasma follows Henry's law: dissolved amount is proportional to partial pressure, so 100% oxygen at 2.0-2.4 ATA multiplies it, letting plasma carry oxygen into areas red cells cannot yet reach.

At sea level breathing room air, the oxygen your tissues receive is carried almost entirely by haemoglobin, which is roughly 97% saturated. Increasing the oxygen fraction you breathe adds very little to that, because there is almost nowhere left to bind.

The dissolved fraction behaves differently. Oxygen dissolved directly in plasma follows Henry's law: the amount dissolved is proportional to the partial pressure. Breathing 100% oxygen at 2.0-2.4 ATA multiplies that partial pressure many times over, and the dissolved fraction rises with it.

The clinically interesting property of dissolved oxygen is that it travels in plasma rather than in red cells. Plasma reaches places red cells are not currently reaching — through oedematous tissue, across a diffusion gap, into a bed where capillaries have not yet formed. That is the specific claim behind using HBOT on a graft that has no circulation yet.

What does hyperbaric oxygen do beyond simply delivering more oxygen to tissue?

Beyond delivering oxygen, hyperbaric exposure generates reactive oxygen and nitrogen species that act as signalling molecules, influencing growth factor expression, inflammation and vascular behaviour. This drives angiogenesis — new vessel growth into hypoxic tissue — and, per Dong and Jin, reduces local inflammatory factor expression while increasing dermal papilla cell proliferation in laboratory experiments.

Thom's review is worth reading carefully here, because the popular account of HBOT — 'more oxygen gets to the tissue' — is a simplification of what the research describes. His account places the principal mechanisms in the intracellular generation of reactive oxygen and nitrogen species, with those reactive species acting as signalling molecules in cascades that influence growth factor expression, inflammatory response and vascular behaviour.

In other words, hyperbaric oxygen is understood less as a delivery system and more as a signal. That framing explains several observations that pure delivery does not, including why effects persist after a session ends and why repeated exposures matter.

Angiogenesis

The angiogenic claim is that hyperbaric exposure promotes new vessel growth into a hypoxic wound bed, which would shorten the diffusion-dependent period for a graft. This is the mechanism behind HBOT's established use in problem wounds and compromised grafts and flaps, where the evidence Thom describes comes largely from animal studies plus a limited number of clinical trials.

Inflammation

Dong and Jin, writing to the Journal of Cosmetic Dermatology about the Fan trial, proposed that anti-inflammatory effects may account for part of any benefit, citing work on hyperbaric oxygen reducing local inflammatory factor expression. They also reported laboratory experiments on human hair follicle dermal papilla cells showing greater proliferation and PCNA expression after hyperbaric treatment than in controls.

Why doesn't HBOT's plausible mechanism guarantee better hair transplant outcomes?

The Fan trial showed HBOT's mechanism producing a measurable effect that didn't translate into outcome: early shedding fell sharply (27.6% vs 69.1%) and folliculitis/itching fell too, yet nine-month survival (96.9% vs 93.8%) wasn't statistically significant. That may reflect too small a trial to detect a real difference, or shed hair that would have regrown anyway.

Everything above is a reason to test HBOT, not evidence that it works. This distinction gets lost in clinic marketing, and it is the single most common way patients are misled about adjunct treatments.

The Fan trial is instructive precisely because it shows the mechanism producing a measurable effect that did not translate into the outcome. Early shedding fell sharply — 27.6% versus 69.1% — which is consistent with grafts being better supported through the ischaemic window. Folliculitis and itching fell too, consistent with an anti-inflammatory effect. And yet survival at nine months was 96.9% with HBOT and 93.8% without, a gap the study did not find statistically significant.

There are two readings of that. One is that the trial was too small to detect a real three-point difference, which is entirely plausible with 34 patients. The other is that the shed hair was going to regrow anyway — postoperative shedding of the transplanted shaft is normal and the follicle usually survives it — so reducing visible shedding changed the patient's experience in the first month without changing the follicle count at the end.

Both readings are defensible on the data available. Nothing in the published literature currently distinguishes between them.

What would make HBOT's mechanism clinically convincing?

HBOT's mechanism would become clinically persuasive with a study large enough to detect a small survival difference, following patients to twelve months rather than nine, counting hairs in a defined recipient zone, and randomising enough patients that a small difference wouldn't vanish into noise — a bar none of the four published studies clears.

Sources

1. Thom SR. Hyperbaric oxygen: its mechanisms and efficacy. Plastic and Reconstructive Surgery, 2011;127 Suppl 1:131S-141S. pubmed.ncbi.nlm.nih.gov/21200283
2. Parsley WM, Perez-Meza D. Review of factors affecting the growth and survival of follicular grafts. Journal of Cutaneous and Aesthetic Surgery, 2010;3(2). jcasonline.com
3. Fan Z, Gan Y, Qu Q, Wang J, Lunan Y, Liu B, Chen R, Hu Z, Miao Y. The effect of hyperbaric oxygen therapy combined with hair transplantation surgery for the treatment of alopecia. Journal of Cosmetic Dermatology, 2021;20(3):917-921. pubmed.ncbi.nlm.nih.gov/32770782
4. Dong X, Jin X. The effect of hyperbaric oxygen therapy combined with hair transplantation surgery for the treatment of alopecia [letter to the editor]. Journal of Cosmetic Dermatology, 2021. doi.org/10.1111/jocd.14131
5. Bernstein RM, Rassman WR. Graft Anchoring in Hair Transplantation. Dermatologic Surgery, 2006;32(2):198-204. pubmed.ncbi.nlm.nih.gov/16442039

This article summarises published research and standard clinical practice. It is general educational information, not medical advice, and it does not replace the instructions your own surgical team gives you. Where their guidance differs from anything here, follow theirs.